This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
Enveric Biosciences announces issuance of U.S. patent
Enveric Biosciences (ENVB) announced the issuance of U.S. Patent No. 12,492,179 entitled, “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” with claims to compositions and methods of treatment for novel molecules with the potential to be developed for mental health disorders. The ‘179 patent expands the protection of Enveric’s pipeline of potentially neuroplastogenic and non-hallucinogenic molecules.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENVB:
Disclaimer & DisclosureReport an Issue
- Enveric Biosciences files to sell 882,627 shares of common stock for holders
- Enveric Biosciences Secures $3.1M Through Warrant Exercise
- Enveric Biosciences trading resumes
- Enveric Biosciences announces exercise of warrants for $3.1M gross proceeds
- Enveric Biosciences trading halted, volatility trading pause
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
